Potential novel pharmacological therapies for myocardial remodelling
Open Access
- 29 October 2008
- journal article
- review article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 81 (3), 519-527
- https://doi.org/10.1093/cvr/cvn317
Abstract
Left ventricular (LV) remodelling remains an important treatment target in patients after myocardial infarction (MI) and chronic heart failure (CHF). Accumulating evidence has supported the concept that beneficial effects of current pharmacological treatment strategies to improve the prognosis in these patients, such as angiotensin-converting enzyme (ACE) inhibition, angiotensin type 1 receptor blocker therapy, and β-blocker therapy, are related, at least in part, to their effects on LV remodelling and dysfunction. However, despite modern reperfusion therapy after MI and optimized treatment of patients with CHF, LV remodelling is observed in a substantial proportion of patients and is associated with an adverse clinical outcome. These observations call for novel therapeutic strategies to prevent or even reverse cardiac remodelling. Recent insights from experimental studies have provided new targets for interventions to prevent or reverse LV remodelling, i.e. reduced endothelial nitric oxide (NO) synthase-derived NO availability, activation of cardiac and leukocyte-dependent oxidant stress pathways, inflammatory pathway activation, matrix-metalloproteinase activation, or stem cell transfer and delivery of novel paracrine factors. An important challenge in translating these observations from preclinical studies into clinical treatment strategies relates to the fact that clinical studies are designed on top of established pharmacological therapy, whereas most experimental studies have tested novel interventions without concomitant drug regimens such as ACE inhibitors or β-blockers. Therefore, animal studies may overestimate the effect of potential novel treatment strategies on LV remodelling and dysfunction, since established pharmacological therapies may act, in part, via identical or similar signalling pathways. Nevertheless, preclinical studies provide essential information for identifying potential novel targets, and their potential drawbacks, and are required for developing novel clinical treatment strategies to prevent or reverse LV remodelling and dysfunction.Keywords
This publication has 101 references indexed in Scilit:
- Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heartJCI Insight, 2007
- Metoprolol Reverses Left Ventricular Remodeling in Patients With Asymptomatic Systolic DysfunctionCirculation, 2007
- Inducible Nitric Oxide Synthase Deficiency Protects the Heart From Systolic Overload–Induced Ventricular Hypertrophy and Congestive Heart FailureCirculation Research, 2007
- Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort studyEuropean Heart Journal, 2007
- Role of Oxidative Stress in Cardiac Hypertrophy and RemodelingHypertension, 2007
- Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repairProceedings of the National Academy of Sciences, 2007
- Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failureJCI Insight, 2005
- Effect of Captopril on Progressive Ventricular Dilatation after Anterior Myocardial InfarctionNew England Journal of Medicine, 1988
- Indomethacin-induced scar thinning after experimental myocardial infarction.Circulation, 1983